Next Issue
Volume 2, June
Previous Issue
Volume 1, December
 
 

Lymphatics, Volume 2, Issue 1 (March 2024) – 3 articles

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Select all
Export citation of selected articles as:
18 pages, 633 KiB  
Review
Paraneoplastic Syndromes in Hodgkin’s Lymphoma
by Yamna Jadoon, Goutham Patil, Chandravathi Loke and Prarthna V. Bhardwaj
Lymphatics 2024, 2(1), 25-42; https://doi.org/10.3390/lymphatics2010003 - 6 Feb 2024
Viewed by 3377
Abstract
Hodgkin’s lymphoma (HL) is a monoclonal lymphoid neoplasm that is mainly characterized by multinucleated Reed–Sternberg cells on a background of non-neoplastic inflammatory cells. The incidence rate of Hodgkin’s lymphoma is 2.5 new cases per 100,000 people per year (1). Paraneoplastic syndromes are conditions [...] Read more.
Hodgkin’s lymphoma (HL) is a monoclonal lymphoid neoplasm that is mainly characterized by multinucleated Reed–Sternberg cells on a background of non-neoplastic inflammatory cells. The incidence rate of Hodgkin’s lymphoma is 2.5 new cases per 100,000 people per year (1). Paraneoplastic syndromes are conditions that are related to malignancy; however, they are not a result of tumor invasion or compression of malignant tissues. These paraneoplastic syndromes can occur virtually at any point in the disease course, and paraneoplastic syndromes in HL and their various forms are not well studied. In this review article, we will be discussing paraneoplastic syndromes in general and then delve into specific syndromes seen in HL, followed by a brief discourse regarding their early recognition and timely management. Full article
(This article belongs to the Collection Lymphomas)
Show Figures

Figure 1

15 pages, 674 KiB  
Review
A Review of Anti-CD20 Antibodies in the Management of B-Cell Lymphomas
by Himil Mahadevia, Mirdhula Ananthamurugan, Kashish Shah, Atharva Desai and Anuj Shrestha
Lymphatics 2024, 2(1), 10-24; https://doi.org/10.3390/lymphatics2010002 - 5 Jan 2024
Cited by 1 | Viewed by 3414
Abstract
Anti-CD20 monoclonal antibodies (mAbs) have revolutionized the treatment of lymphomas by improving the survival of patients, particularly in conjunction with chemotherapy. Until recently, the gold standard was based on the utilization of Rituximab (RTX) combined with chemotherapy. With our better understanding of monoclonal [...] Read more.
Anti-CD20 monoclonal antibodies (mAbs) have revolutionized the treatment of lymphomas by improving the survival of patients, particularly in conjunction with chemotherapy. Until recently, the gold standard was based on the utilization of Rituximab (RTX) combined with chemotherapy. With our better understanding of monoclonal antibody (mAb) engineering, anti-CD20 mAb therapy has evolved to enhance clinical outcomes by improving pharmacokinetics, safety, activity and immunogenicity. Efforts to improve the on-targeting CD20 expressed on lymphomas through novel bioengineering techniques have led to the development of newer anti-CD20 mAbs that have accentuated complement-dependent cytotoxicity (CDC), antibody-dependent cell medicated cytotoxicity (ADCC), and/or a direct killing effect. There are several anti-CD20 monoclonal antibodies that have been evaluated for the treatment of lymphomas, some of which are now approved in addition to RTX. Full article
(This article belongs to the Collection Lymphomas)
Show Figures

Figure 1

9 pages, 33218 KiB  
Brief Report
Motion Management: The Road Map to Accurate Radiation Treatment Delivery
by Bouthaina Dabaja, Susan Wu and Nicholas J. Short
Lymphatics 2024, 2(1), 1-9; https://doi.org/10.3390/lymphatics2010001 - 1 Jan 2024
Viewed by 1291
Abstract
Radiation therapy is a key contributor to positive outcomes in hematological malignancies. However, this is contingent on minimizing the exposure of critical normal organs. The introduction of computed tomography (CT) for radiation treatment planning and the development of sophisticated dose calculation algorithms has [...] Read more.
Radiation therapy is a key contributor to positive outcomes in hematological malignancies. However, this is contingent on minimizing the exposure of critical normal organs. The introduction of computed tomography (CT) for radiation treatment planning and the development of sophisticated dose calculation algorithms has transformed the radiation therapy field and made it possible to transition from conventional involved-field radiation to modern involved-site radiation therapy. Thanks to rapid advances in drug discovery, treatment strategies for many hematological malignancies have evolved to incorporate targeted and cellular therapies, in some cases even allowing the replacement of chemotherapy. As a result, new opportunities have been created for radiation to address relapses after more lines of therapy, identify disease-involving sanctuary sites, and bridge to the subsequent therapy. When considering radiation in patients receiving novel therapies, who may also be more heavily pretreated, respecting the critical and normal structures at all costs is imperative. In this document, we will describe modern techniques used to deliver state-of-the-art radiation therapy and practical considerations to ensure the accurate treatment of the target while avoiding normal organs at risk. Full article
(This article belongs to the Collection Radiation Oncology)
Show Figures

Graphical abstract

Previous Issue
Next Issue
Back to TopTop